Key Points
-
The bone marrow niche supports the integration of two major organ systems — the skeleton and the marrow
-
The niche is a unique microenvironment that is crucial for haematopoietic stem cell quiescence
-
Important features of the niche include its cellular components, hypoxia, extracellular matrices, cytokines and growth factors, and vascularization
-
Multiple myeloma and other cancer cells hijack and alter the bone marrow niche, and are altered by the niche in turn; thus, targeting niche–cancer interactions is a promising therapeutic avenue
-
Novel in vitro and in vivo models of the bone marrow niche and cancer cells enable us to better understand interactions between cancer and bone marrow niche cells
-
A more complete understanding of the biology of the unique bone marrow microenvironment must remain a major research priority
Abstract
The bone marrow niche consists of stem and progenitor cells destined to become mature cells such as haematopoietic elements, osteoblasts or adipocytes. Marrow cells, influenced by endocrine, paracrine and autocrine factors, ultimately function as a unit to regulate bone remodelling and haematopoiesis. Current evidence highlights that the bone marrow niche is not merely an anatomic compartment; rather, it integrates the physiology of two distinct organ systems, the skeleton and the marrow. The niche has a hypoxic microenvironment that maintains quiescent haematopoietic stem cells (HSCs) and supports glycolytic metabolism. In response to biochemical cues and under the influence of neural, hormonal, and biochemical factors, marrow stromal elements, such as mesenchymal stromal cells (MSCs), differentiate into mature, functioning cells. However, disruption of the niche can affect cellular differentiation, resulting in disorders ranging from osteoporosis to malignancy. In this Review, we propose that the niche reflects the vitality of two tissues — bone and blood — by providing a unique environment for stem and stromal cells to flourish while simultaneously preventing disproportionate proliferation, malignant transformation or loss of the multipotent progenitors required for healing, functional immunity and growth throughout an organism's lifetime. Through a fuller understanding of the complexity of the niche in physiologic and pathologic states, the successful development of more-effective therapeutic approaches to target the niche and its cellular components for the treatment of rheumatic, endocrine, neoplastic and metabolic diseases becomes achievable.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ushio-Fukai, M. & Rehman, J. Redox and metabolic regulation of stem/progenitor cells and their niche. Antioxid. Redox Signal. 21, 1587–1590 (2014).
Bianco, P. 'Mesenchymal' stem cells. Annu. Rev. Cell Dev. Biol. 30, 677–704 (2014).
Scadden, D. T. The stem-cell niche as an entity of action. Nature 441, 1075–1079 (2006).
De Miguel, M. P., Alcaina, Y., de la Maza, D. S. & Lopez-Iglesias, P. Cell metabolism under microenvironmental low oxygen tension levels in stemness, proliferation and pluripotency. Curr. Mol. Med. 14, 343–359 (2015).
Gunjal, P. M. et al. Evidence for induction of a tumor metastasis-receptive microenvironment for ovarian cancer cells in bone marrow and other organs as an unwanted and underestimated side effect of chemotherapy/radiotherapy. J. Ovarian Res. 8, 20 (2015).
Meleshina, A. V. et al. Influence of mesenchymal stem cells on metastasis development in mice in vivo. Stem Cell Res. Ther. 6, 15 (2015).
Bianco, P., Robey, P. G., Saggio, I. & Riminucci, M. 'Mesenchymal' stem cells in human bone marrow (skeletal stem cells): a critical discussion of their nature, identity, and significance in incurable skeletal disease. Hum. Gene Ther. 21, 1057–1066 (2010).
Méndez-Ferrer, S. et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 466, 829–834 (2010).
Köhler, A., Geiger, H. & Gunzer, M. Imaging hematopoietic stem cells in the marrow of long bones in vivo. Methods Mol. Biol. 750, 215–224 (2011).
Manolagas, S. C. & Jilka, R. L. Bone marrow, cytokines, and bone remodeling—emerging insights into the pathophysiology of osteoporosis. N. Engl. J. Med. 332, 305–311 (1995).
Bianco, P. et al. The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine. Nat. Med. 19, 35–42 (2013).
Wong, R. S. Mesenchymal stem cells: angels or demons? J. Biomed. Biotechnol. 2011, 459510 (2011).
Calvi, L. M. et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 425, 841–846 (2003).
Bianco, P. Minireview: the stem cell next door: skeletal and hematopoietic stem cell 'niches' in bone. Endocrinology 152, 2957–2962 (2011).
Ellis, S. L. & Nilsson, S. K. The location and cellular composition of the hemopoietic stem cell niche. Cytotherapy 14, 135–143 (2012).
Morrison, S. J. & Scadden, D. T. The bone marrow niche for haematopoietic stem cells. Nature 505, 327–334 (2014).
Bianco, P., Sacchetti, B. & Riminucci, M. Osteoprogenitors and the hematopoietic microenvironment. Best Pract. Res. Clin. Haematol. 24, 37–47 (2011).
Sacchetti, B. et al. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell 131, 324–336 (2007).
Morikawa, S. et al. Prospective identification, isolation, and systemic transplantation of multipotent mesenchymal stem cells in murine bone marrow. J. Exp. Med. 206, 2483–2496 (2009).
Liu, Y. et al. Osterix–Cre labeled progenitor cells contribute to the formation and maintenance of the bone marrow stroma. PLoS ONE 8, e71318 (2013).
Kim, S. W. et al. Intermittent parathyroid hormone administration converts quiescent lining cells to active osteoblasts. J. Bone Miner. Res. 27, 2075–2084 (2012).
Asada, N. & Katayama, Y. Regulation of hematopoiesis in endosteal microenvironments. Int. J. Hematol. 99, 679–684 (2014).
Huber, B. C., Grabmaier, U. & Brunner, S. Impact of parathyroid hormone on bone marrow-derived stem cell mobilization and migration. World J. Stem Cells 6, 637–643 (2014).
Kuznetsov, S. A. et al. The interplay of osteogenesis and hematopoiesis: expression of a constitutively active PTH/PTHrP receptor in osteogenic cells perturbs the establishment of hematopoiesis in bone and of skeletal stem cells in the bone marrow. J. Cell Biol. 167, 1113–1122 (2004).
Coskun, S. et al. Development of the fetal bone marrow niche and regulation of HSC quiescence and homing ability by emerging osteolineage cells. Cell Rep. 9, 581–590 (2014).
Omatsu, Y., Seike, M., Sugiyama, T., Kume, T. & Nagasawa, T. Foxc1 is a critical regulator of haematopoietic stem/progenitor cell niche formation. Nature 508, 536–540 (2014).
Rosen, C. J., Ackert-Bicknell, C., Rodriguez, J. P. & Pino, A. M. Marrow fat and the bone microenvironment: developmental, functional, and pathological implications. Crit. Rev. Eukaryot. Gene Expr. 19, 109–124 (2009).
Rosen, C. J. & Bouxsein, M. L. Mechanisms of disease: is osteoporosis the obesity of bone? Nat. Clin. Pract. Rheumatol. 2, 35–43 (2006).
Gordon, M. Y. Stem cells and the microenvironment in aplastic anaemia. Br. J. Haematol. 86, 190–192 (1994).
Fazeli, P. K. et al. Marrow fat and bone — new perspectives. J. Clin. Endocrinol. Metab. 98, 935–945 (2013).
Scheller, E. L. & Rosen, C. J. What's the matter with MAT? Marrow adipose tissue, metabolism, and skeletal health. Ann. NY Acad. Sci. 1311, 14–30 (2014).
Naveiras, O. et al. Bone-marrow adipocytes as negative regulators of the haematopoietic microenvironment. Nature 460, 259–263 (2009).
Scheller, E. L. et al. Use of osmium tetroxide staining with microcomputerized tomography to visualize and quantify bone marrow adipose tissue in vivo. Methods Enzymol. 537, 123–139 (2014).
Bredella, M. A. et al. Determinants of bone microarchitecture and mechanical properties in obese men. J. Clin. Endocrinol. Metab. 97, 4115–4122 (2012).
Cawthorn, W. P. et al. Bone marrow adipose tissue is an endocrine organ that contributes to increased circulating adiponectin during caloric restriction. Cell Metab. 20, 368–375 (2014).
Bornstein, S. et al. FGF-21 and skeletal remodeling during and after lactation in C57BL6 mice. Endocrinology 155, 3516–3526 (2014).
Ackert-Bicknell, C. L. et al. Strain-specific effects of rosiglitazone on bone mass, body composition, and serum insulin-like growth factor-I. Endocrinology 150, 1330–1340 (2009).
Chang, M. K. et al. Osteal tissue macrophages are intercalated throughout human and mouse bone lining tissues and regulate osteoblast function in vitro and in vivo. J. Immunol. 181, 1232–1244 (2008).
Winkler, I. G. et al. Bone marrow macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs. Blood 116, 4815–4828 (2010).
Alexander, K. A. et al. Osteal macrophages promote in vivo intramembranous bone healing in a mouse tibial injury model. J. Bone Miner. Res. 26, 1517–1532 (2011).
Pettit, A. R., Chang, M. K., Hume, D. A. & Raggatt, L.-J. Osteal macrophages: a new twist on coupling during bone dynamics. Bone 43, 976–982 (2008).
Casanova-Acebes, M., A-González, N., Weiss, L. A. & Hidalgo, A. Innate immune cells as homeostatic regulators of the hematopoietic niche. Int. J. Hematol. 99, 685–694 (2014).
Baschuk, N., Rautela, J. & Parker, B. S. Bone specific immunity and its impact on metastasis. BoneKEy Rep. 4, 665 (2015).
Garhyan, J. et al. Preclinical and clinical evidence of mycobacterium tuberculosis persistence in the hypoxic niche of bone marrow mesenchymal stem cells after therapy. Am. J. Pathol. 185, 1924–1934 (2015).
Wesseling-Perry, K. The BRC canopy: an important player in bone remodeling. Am. J. Pathol. 184, 924–926 (2014).
Jensen, P. R., Andersen, T. L., Hauge, E.-M., Bollerslev, J. & Delaissé, J.-M. A joined role of canopy and reversal cells in bone remodeling—lessons from glucocorticoid-induced osteoporosis. Bone 73, 16–23 (2015).
Zhao, M. et al. Megakaryocytes maintain homeostatic quiescence and promote post-injury regeneration of hematopoietic stem cells. Nat. Med. 20, 1321–1326 (2014).
Bruns, I. et al. Megakaryocytes regulate hematopoietic stem cell quiescence through CXCL4 secretion. Nat. Med. 20, 1315–1320 (2014).
Winkler I. G. et al. Vascular niche E-selectin regulates hematopoietic stem cell dormancy, self renewal and chemoresistance. Nat. Med. 18, 1651–1657 (2012).
Greenbaum, A. et al. CXCL12 in early mesenchymal progenitors is required for haematopoietic stem-cell maintenance. Nature 495, 227–230 (2013).
Hooper, A. T. et al. Engraftment and reconstitution of hematopoiesis is dependent on VEGFR2-mediated regeneration of sinusoidal endothelial cells. Cell Stem Cell 4, 263–274 (2009).
Ding, L., Saunders, T. L., Enikolopov, G. & Morrison, S. J. Endothelial and perivascular cells maintain haematopoietic stem cells. Nature 481, 457–462 (2012).
Méndez-Ferrer, S., Lucas, D., Battista, M. & Frenette, P. S. Haematopoietic stem cell release is regulated by circadian oscillations. Nature 452, 442–427 (2008).
Kotova, P. D. et al. Functional expression of adrenoreceptors in mesenchymal stromal cells derived from the human adipose tissue. Biochim. Biophys. Acta 1843, 1899–1908 (2014).
Xie, Y. et al. Detection of functional haematopoietic stem cell niche using real-time imaging. Nature 457, 97–101 (2009).
Hu, X. et al. Severe hypoxia exerts parallel and cell-specific regulation of gene expression and alternative splicing in human mesenchymal stem cells. BMC Genomics 15, 303 (2014).
Krock, B. L. et al. The aryl hydrocarbon receptor nuclear translocator is an essential regulator of murine hematopoietic stem cell viability. Blood 125, 3263–3272 (2015).
Forristal, C. E. & Levesque, J.-P. Targeting the hypoxia-sensing pathway in clinical hematology. Stem Cells Transl. Med. 3, 135–140 (2014).
Winkler, I. G. et al. Positioning of bone marrow hematopoietic and stromal cells relative to blood flow in vivo: serially reconstituting hematopoietic stem cells reside in distinct nonperfused niches. Blood 116, 375–385 (2010).
Imanirad, P. & Dzierzak, E. Hypoxia and HIFs in regulating the development of the hematopoietic system. Blood Cells. Mol. Dis. 51, 256–263 (2013).
Miharada, K. et al. Hematopoietic stem cells are regulated by Cripto, as an intermediary of HIF-1α in the hypoxic bone marrow niche. Ann. NY Acad. Sci. 1266, 55–62 (2012).
D'Angelo, G., Duplan, E., Boyer, N., Vigne, P. & Frelin, C. Hypoxia up-regulates prolyl hydroxylase activity: a feedback mechanism that limits HIF-1 responses during reoxygenation. J. Biol. Chem. 278, 38183–38187 (2003).
Palomäki, S. et al. HIF-1α is upregulated in human mesenchymal stem cells. Stem Cells 31, 1902–1909 (2013).
Andrade, P. Z. et al. Ex vivo expansion of cord blood haematopoietic stem/progenitor cells under physiological oxygen tensions: clear-cut effects on cell proliferation, differentiation and metabolism. J. Tissue Eng. Regen. Med. http://dx.doi.org/10.1002/term.1731 (2013).
Liu, X. et al. Maintenance of mouse hematopoietic stem cells ex vivo by reprogramming cellular metabolism. Blood 125, 1562–1565 (2015).
Kocabas, F., Zheng, J., Zhang, C. & Sadek, H. A. Metabolic characterization of hematopoietic stem cells. Methods Mol. Biol. 1185, 155–164 (2014).
Wagegg, M. et al. Hypoxia promotes osteogenesis but suppresses adipogenesis of human mesenchymal stromal cells in a hypoxia-inducible factor-1 dependent manner. PLoS ONE 7, e46483 (2012).
Duan, X. et al. Vegfa regulates perichondrial vascularity and osteoblast differentiation in bone development. Development 142, 1984–1991 (2015).
Regan, J. N. et al. Up-regulation of glycolytic metabolism is required for HIF1α-driven bone formation. Proc. Natl. Acad. Sci. USA 111, 8673–8678 (2014).
Chang, S.-H. et al. Association between metformin use and transformation of monoclonal gammopathy of undetermined significance to multiple myeloma in U.S. veterans with diabetes mellitus: a population-based cohort study. Lancet Haematol. 2, e30–e36 (2015).
Jang, W. G., Kim, E. J., Lee, K.-N., Son, H.-J. & Koh, J.-T. AMP-activated protein kinase (AMPK) positively regulates osteoblast differentiation via induction of Dlx5-dependent Runx2 expression in MC3T3E1 cells. Biochem. Biophys. Res. Commun. 404, 1004–1009 (2011).
Guntur, A. R., Le, P. T., Farber, C. R. & Rosen, C. J. Bioenergetics during calvarial osteoblast differentiation reflect strain differences in bone mass. Endocrinology 155, 1589–1595 (2014).
Esen, E. & Long, F. Aerobic glycolysis in osteoblasts. Curr. Osteoporos. Rep. 12, 433–438 (2014).
Esen, E., Lee, S.-Y., Wice, B. M. & Long, F. PTH promotes bone anabolism by stimulating aerobic glycolysis via IGF signaling. J. Bone Miner. Res. http://dx.doi.org/10.1002/jbmr.2556 (2015).
Nagasawa, T. CXC chemokine ligand 12 (CXCL12) and its receptor CXCR4. J. Mol. Med. (Berl.) 92, 433–439 (2014).
Nervi, B., Link, D. C. & DiPersio, J. F. Cytokines and hematopoietic stem cell mobilization. J. Cell. Biochem. 99, 690–705 (2006).
Nguyen, T. M. et al. EphB4 expressing stromal cells exhibit an enhanced capacity for hematopoietic stem cell maintenance. Stem Cells 33, 2838–2849 (2015).
Krevvata, M. et al. Inhibition of leukemia cell engraftment and disease progression in mice by osteoblasts. Blood 124, 2834–2846 (2014).
Kode, A. et al. FoxO1-dependent induction of acute myeloid leukemia by osteoblasts in mice. Leukemia http://dx.doi.org/10.1038/leu.2015.161 (2015).
Guise, T. A. et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin. Cancer Res. 12, 6213s–6216s (2006).
Weilbaecher, K. N., Guise, T. A. & McCauley, L. K. Cancer to bone: a fatal attraction. Nat. Rev. Cancer 11, 411–425 (2011).
Cui, Q. et al. Targeting myeloma-osteoclast interaction with Vγ9Vδ2 T cells. Int. J. Hematol. 94, 63–70 (2011).
Le Gall, C. et al. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. Cancer Res. 67, 9894–9902 (2007).
Jones, D. H. et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440, 692–696 (2006).
Roodman, G. D. Genes associate with abnormal bone cell activity in bone metastasis. Cancer Metastasis Rev. 31, 569–578 (2012).
Medyouf, H. et al. Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit. Cell Stem Cell 14, 824–837 (2014).
Reagan, M. R. & Ghobrial, I. M. Multiple myeloma mesenchymal stem cells: characterization, origin, and tumor-promoting effects. Clin. Cancer Res. 18, 342–349 (2012).
Reagan, M. R., Liaw, L., Rosen, C. J. & Ghobrial, I. M. Dynamic interplay between bone and multiple myeloma: emerging roles of the osteoblast. Bone 75, 161–169 (2015).
Schepers, K. et al. Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche. Cell Stem Cell 13, 285–299 (2013).
Raaijmakers, M. H. Myelodysplastic syndromes: revisiting the role of the bone marrow microenvironment in disease pathogenesis. Int. J. Hematol. 95, 17–25 (2012).
Shiozawa, Y. & Taichman, R. S. Cancer stem cells and the bone marrow microenvironment. BoneKEy Rep. 1, 48 (2012).
Kang, Y. & Pantel, K. Tumor cell dissemination: emerging biological insights from animal models and cancer patients. Cancer Cell 23, 573–581 (2013).
Chantry, A. D. et al. Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo. J. Bone Miner. Res. 25, 2633–2646 (2010).
Kingsley, L. A., Fournier, P. G., Chirgwin, J. M. & Guise, T. A. Molecular biology of bone metastasis. Mol. Cancer Ther. 6, 2609–2617 (2007).
Kimura, T. et al. Targeting of bone-derived insulin-like growth factor-II by a human neutralizing antibody suppresses the growth of prostate cancer cells in a human bone environment. Clin. Cancer Res. 16, 121–129 (2010).
Kovacic, N., Croucher, P. I. & McDonald, M. M. Signaling between tumor cells and the host bone marrow microenvironment. Calcif. Tissue Int. 94, 125–139 (2013).
Ottewell, P. D., O'Donnell, L. & Holen, I. Molecular alterations that drive breast cancer metastasis to bone. BoneKEy Rep. 4, 643 (2015).
Suva, L. J., Washam, C., Nicholas, R. W. & Griffin, R. J. Bone metastasis: mechanisms and therapeutic opportunities. Nat. Rev. Endocrinol. 7, 208–218 (2011).
Martinez-Outschoorn, U., Sotgia, F. & Lisanti, M. P. Tumor microenvironment and metabolic synergy in breast cancers: critical importance of mitochondrial fuels and function. Semin. Oncol. 41, 195–216 (2014).
Olechnowicz, S. W. & Edwards, C. M. Contributions of the host microenvironment to cancer-induced bone disease. Cancer Res. 74, 1625–1631 (2014).
Raaijmakers, M. H. Niche contributions to oncogenesis: emerging concepts and implications for the hematopoietic system. Haematologica 96, 1041–1048 (2011).
Dawson, M. R., Chae, S.-S., Jain, R. K. & Duda, D. G. Direct evidence for lineage-dependent effects of bone marrow stromal cells on tumor progression. Am. J. Cancer Res. 1, 144–154 (2011).
Asimakopoulos, F. et al. Macrophages in multiple myeloma: emerging concepts and therapeutic implications. Leuk. Lymphoma 54, 2112–2121 (2013).
Logothetis, C. J. & Lin, S.-H. Osteoblasts in prostate cancer metastasis to bone. Nat. Rev. Cancer 5, 21–28 (2005).
Hardaway, A. L., Herroon, M. K., Rajagurubandara, E. & Podgorski, I. Bone marrow fat: linking adipocyte-induced inflammation with skeletal metastases. Cancer Metastasis Rev. 33, 527–543 (2014).
Compton, J. T. & Lee, F. Y. A review of osteocyte function and the emerging importance of sclerostin. J. Bone Joint Surg. Am. 96, 1659–1668 (2014).
McMillin, D. W. et al. Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat. Med. 16, 483 (2010).
Liu, S. et al. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res. 71, 614–624 (2011).
Reagan, M. R. & Ghobrial, I. M. Multiple myeloma-mesenchymal stem cells: characterization, origin, and tumor-promoting effects. Clin. Cancer Res. 18, 342–349 (2012).
Reagan, M. R. et al. Investigating osteogenic differentiation in multiple myeloma using a novel 3D bone marrow niche model. Blood 124, 3250–3259 (2014).
Walenda, T. et al. Feedback signals in myelodysplastic syndromes: increased self-renewal of the malignant clone suppresses normal hematopoiesis. PLoS Comput. Biol. 10, e1003599 (2014).
Kawano, Y. et al. Targeting the bone marrow microenvironment in multiple myeloma. Immunol. Rev. 263, 160–172 (2015).
Moschetta, M. et al. Role of endothelial progenitor cells in cancer progression. Biochim. Biophys. Acta 1846, 26–39 (2014).
Roccaro, A. M. et al. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J. Clin. Invest. 123, 1542–1555 (2013).
Evans, A. G. & Calvi, L. M. Notch signaling in the malignant bone marrow microenvironment: implications for a niche-based model of oncogenesis. Ann. NY Acad. Sci. 1335, 63–77 (2015).
Van den Berk, L. C. J. et al. Disturbed CXCR4/CXCL12 axis in paediatric precursor B-cell acute lymphoblastic leukaemia. Br. J. Haematol. 166, 240–249 (2014).
Glavey, S. V. et al. The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma. Blood 124, 1765–1776 (2014).
Glavey, S. V. et al. The cancer glycome: carbohydrates as mediators of metastasis. Blood Rev. 29, 269–279 (2015).
Ellis, S. L. et al. The relationship between bone, hemopoietic stem cells, and vasculature. Blood 118, 1516–1524 (2011).
Ottewell, P. D., O'Donnell, L. & Holen, I. Molecular alterations that drive breast cancer metastasis to bone. BoneKEy Rep. 4, 643 (2015).
Roccaro, A. M. et al. SDF-1 inhibition targets the bone marrow niche for cancer therapy. Cell Rep. 9, 118–128 (2014).
Harms, J. F. et al. A small molecule antagonist of the αvβ3 integrin suppresses MDA-MB-435 skeletal metastasis. Clin. Exp. Metastasis 21, 119–128 (2004).
Kaplan, R. N., Psaila, B. & Lyden, D. Niche-to-niche migration of bone-marrow-derived cells. Trends Mol. Med. 13, 72–81 (2007).
Sullivan, C. et al. Functional ramifications for the loss of P-selectin expression on hematopoietic and leukemic stem cells. PLoS ONE 6, e26246 (2011).
Croset, M., Kan, C. & Clézardin, P. Tumour-derived miRNAs and bone metastasis. BoneKEy Rep. 4, 688 (2015).
Runnels, J. M. et al. Optical techniques for tracking multiple myeloma engraftment, growth, and response to therapy. J. Biomed. Opt. 16, 011006 (2011).
Azab, A. K. et al. Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. Blood 119, 5782–5794 (2012).
Muz, B., de la Puente, P., Azab, F., Luderer, M. & Azab, A. K. Hypoxia promotes stem cell-like phenotype in multiple myeloma cells. Blood Cancer J. 4, e262 (2014).
Xiang, L. et al. Hypoxia-inducible factor 1 mediates TAZ expression and nuclear localization to induce the breast cancer stem cell phenotype. Oncotarget 5, 12509–12527 (2014).
Gezer, D., Vukovic, M., Soga, T., Pollard, P. J. & Kranc, K. R. Concise review: genetic dissection of hypoxia signaling pathways in normal and leukemic stem cells. Stem Cells 32, 1390–1397 (2014).
Borsi, E. et al. Hypoxia inducible factor-1 α as a therapeutic target in multiple myeloma. Oncotarget 5, 1779–1792 (2014).
Maiso, P. et al. Metabolic signature identifies novel targets for drug resistance in multiple myeloma. Cancer Res. 75, 2071–2082 (2015).
Yu, C. et al. Prostate cancer and parasitism of the bone hematopoietic stem cell niche. Crit. Rev. Eukaryot. Gene Expr. 22, 131–148 (2012).
Kim, J. K. et al. TBK1 regulates prostate cancer dormancy through mTOR inhibition. Neoplasia 15, 1064–1074 (2013).
Pedersen, E. A., Shiozawa, Y., Pienta, K. J. & Taichman, R. S. The prostate cancer bone marrow niche: more than just 'fertile soil'. Asian J. Androl. 14, 423–427 (2012).
Martínez-Jaramillo, G., Vela-Ojeda, J., Flores-Guzmán, P. & Mayani, H. In vitro growth of hematopoietic progenitors and stromal bone marrow cells from patients with multiple myeloma. Leuk. Res. 35, 250–255 (2011).
Bruns, I. et al. Multiple myeloma-related deregulation of bone marrow-derived CD34+ hematopoietic stem and progenitor cells. Blood 120, 2620–2630 (2012).
Mundy, G. R. Mechanisms of osteolytic bone destruction. Bone 12, S1–S6 (1991).
Swami, A. et al. Engineered nanomedicine for myeloma and bone microenvironment targeting. Proc. Natl. Acad. Sci. USA 111, 10287–10292 (2014).
Jones, M. D. et al. A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genes. Clin. Cancer Res. 16, 4978–4989 (2010).
Kaplan, R. N. et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438, 820–827 (2005).
Cox, T. R. et al. The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. Nature 522, 106–110 (2015).
Martinez, L. M. et al. Changes in the peripheral blood and bone marrow from untreated advanced breast cancer patients that are associated with the establishment of bone metastases. Clin. Exp. Metastasis 31, 213–232 (2014).
Benito-Martin, A., Di Giannatale, A., Ceder, S. & Peinado, H. The new deal: a potential role for secreted vesicles in innate immunity and tumor progression. Front. Immunol. 6, 66 (2015).
Zhang, Y. & Wang, X.-F. A niche role for cancer exosomes in metastasis. Nat. Cell Biol. 17, 709–711 (2015).
Sceneay, J., Smyth, M. J. & Möller, A. The pre-metastatic niche: finding common ground. Cancer Metastasis Rev. 32, 449–464 (2013).
Liu, S. et al. Vascular endothelial growth factor plays a critical role in the formation of the pre-metastatic niche via prostaglandin E2. Oncol. Rep. 32, 2477–2484 (2014).
Kerr, B. A., McCabe, N. P., Feng, W. & Byzova, T. V. Platelets govern pre-metastatic tumor communication to bone. Oncogene 32, 4319–4324 (2013).
Phoenix, K. N., Vumbaca, F., Fox, M. M., Evans, R. & Claffey, K. P. Dietary energy availability affects primary and metastatic breast cancer and metformin efficacy. Breast Cancer Res. Treat. 123, 333–344 (2010).
Brinton, L. T., Sloane, H. S., Kester, M. & Kelly, K. A. Formation and role of exosomes in cancer. Cell. Mol. Life Sci. 72, 659–671 (2014).
Raaijmakers, M. H. et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 464, 852–857 (2010).
Sasser, A. K. et al. Human bone marrow stromal cells enhance breast cancer cell growth rates in a cell line-dependent manner when evaluated in 3D tumor environments. Cancer Lett. 254, 255–264 (2007).
Mastro, A. M. & Vogler, E. A. A three-dimensional osteogenic tissue model for the study of metastatic tumor cell interactions with bone. Cancer Res. 69, 4097–4100 (2009).
Sieh, S., Lubik, A. A., Clements, J. A., Nelson, C. C. & Hutmacher, D. W. Interactions between human osteoblasts and prostate cancer cells in a novel 3D in vitro model. Organogenesis 6, 181–188
Maréchal, M. et al. Bone augmentation with autologous periosteal cells and two different calcium phosphate scaffolds under an occlusive titanium barrier: an experimental study in rabbits. J. Periodontol. 79, 896–904 (2008).
Augst, A. et al. Effects of chondrogenic and osteogenic regulatory factors on composite constructs grown using human mesenchymal stem cells, silk scaffolds and bioreactors. J. R. Soc. Interface 5, 929–939 (2008).
Marolt, D. et al. Bone and cartilage tissue constructs grown using human bone marrow stromal cells, silk scaffolds and rotating bioreactors. Biomaterials 27, 6138–6149 (2006).
Ferrarini, M. et al. Ex-vivo dynamic 3D culture of human tissues in the RCCS™ bioreactor allows the study of multiple myeloma biology and response to therapy. PLoS ONE 8, e71613 (2013).
Meinel, L. et al. Engineering bone-like tissue in vitro using human bone marrow stem cells and silk scaffolds. J. Biomed. Mater. Res. A 71, 25–34 (2004).
Hsiao, A. Y. et al. Microfluidic system for formation of PC-3 prostate cancer co-culture spheroids. Biomaterials 30, 3020–3027 (2009).
Pallotta, I., Lovett, M., Kaplan, D. L. & Balduini, A. Three-dimensional system for the in vitro study of megakaryocytes and functional platelet production using silk-based vascular tubes. Tissue Eng. Part C Methods 17, 1223–1232 (2011).
Wray, L. S. et al. A silk-based scaffold platform with tunable architecture for engineering critically-sized tissue constructs. Biomaterials 33, 9214–9224 (2012).
Di Buduo, C. A. et al. Programmable 3D silk bone marrow niche for platelet generation ex vivo and modeling of megakaryopoiesis pathologies. Blood 125, 2254–2264 (2015).
Roccaro, A. M. et al. CXCR4 regulates extra-medullary myeloma through epithelial-mesenchymal-transition-like transcriptional activation. Cell Rep. 12, 622–635 (2015).
Hu, Z., Zhang, Z., Guise, T. & Seth, P. Systemic delivery of an oncolytic adenovirus expressing soluble transforming growth factor-β receptor II-Fc fusion protein can inhibit breast cancer bone metastasis in a mouse model. Hum. Gene Ther. 21, 1623–1629 (2010).
Paton-Hough, J., Chantry, A. D. & Lawson, M. A. A review of current murine models of multiple myeloma used to assess the efficacy of therapeutic agents on tumour growth and bone disease. Bone 77, 57–68 (2015).
Van der Horst, G. et al. Targeting of αv-integrins in stem/progenitor cells and supportive microenvironment impairs bone metastasis in human prostate cancer. Neoplasia 13, 516–525 (2011).
Fowler, J. A., Mundy, G. R., Lwin, S. T., Lynch, C. C. & Edwards, C. M. A murine model of myeloma that allows genetic manipulation of the host microenvironment. Dis. Model. Mech. 2, 604–611 (2009).
Chesi, M. et al. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell 13, 167–180 (2008).
Schueler, J. et al. Intratibial injection of human multiple myeloma cells in NOD/SCID IL-2Rγ(null) mice mimics human myeloma and serves as a valuable tool for the development of anticancer strategies. PLoS ONE 8, e79939 (2013).
Tassone, P. et al. A SCID-hu in vivo model of human Waldenström macroglobulinemia. Blood 106, 1341–1345 (2005).
Libouban, H. The use of animal models in multiple myeloma. Morphologie 99, 63–72 (2015).
Goldstein, R. H., Reagan, M. R., Anderson, K., Kaplan, D. L. & Rosenblatt, M. Human bone marrow-derived MSCs can home to orthotopic breast cancer tumors and promote bone metastasis. Cancer Res. 70, 10044 (2010).
Reagan, M. R. et al. Stem cell implants for cancer therapy: TRAIL-expressing mesenchymal stem cells target cancer cells in situ. J. Breast Cancer 15, 273–282 (2012).
Moreau, J. E. et al. Tissue-engineered bone serves as a target for metastasis of human breast cancer in a mouse model. Cancer Res. 67, 10304 (2007).
Takayanagi, H. Osteoimmunology in 2014: Two-faced immunology — from osteogenesis to bone resorption. Nat. Rev. Rheumatol. 11, 74–76 (2015).
Neer, R. M. et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344, 1434–1441 (2001).
Pennisi, A. et al. The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo. Am. J. Hematol. 84, 6–14 (2009).
Lv, F.-J., Tuan, R. S., Cheung, K. M. & Leung, V. Y. Concise review: the surface markers and identity of human mesenchymal stem cells. Stem Cells 32, 1408–1419 (2014).
Ratajczak, M. Z. Phenotypic and functional characterization of hematopoietic stem cells. Curr. Opin. Hematol. 15, 293–300 (2008).
Liu, Y. et al. Osterix–Cre labeled progenitor cells contribute to the formation and maintenance of the bone marrow stroma. PLoS ONE 8, e71318 (2013).
Acknowledgements
The authors' work is supported by the NIH/NIAMS (AR066120), NIH/NIDDK (R24 DK092759-01), and by a Pilot Project Grant from NIH/NIGMS (P30GM106391) at the Maine Medical Centre Research Institute. The authors' work is also supported in part by the Department of Defence (DoD) Visionary Postdoctoral Fellowship Award, through the Peer Reviewed Cancer Research Program, under Award FY14 DoD Congressionally Directed Medical Research Programs 30 No. (W81XWH-13-1-0390); opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the DoD.
Author information
Authors and Affiliations
Contributions
Both authors contributed equally to researching data for the article, discussion of content, writing and review/editing of manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Reagan, M., Rosen, C. Navigating the bone marrow niche: translational insights and cancer-driven dysfunction. Nat Rev Rheumatol 12, 154–168 (2016). https://doi.org/10.1038/nrrheum.2015.160
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2015.160
This article is cited by
-
Development and application of nanomaterials, nanotechnology and nanomedicine for treating hematological malignancies
Journal of Hematology & Oncology (2023)
-
Continuous Indexing of Fibrosis (CIF): improving the assessment and classification of MPN patients
Leukemia (2023)
-
Bone Marrow Adipose Tissue: Regulation of Osteoblastic Niche, Hematopoiesis and Hematological Malignancies
Stem Cell Reviews and Reports (2023)
-
Serum sclerostin and sympathetic skin response: relationship with myeloma bone disease
The Egyptian Journal of Neurology, Psychiatry and Neurosurgery (2022)
-
Mesenchymal stem cells as a double-edged sword in tumor growth: focusing on MSC-derived cytokines
Cellular & Molecular Biology Letters (2021)